Antibody engineering

US11643437B2

A separated cancer-targeting peptide that consists of a minimum of 2 copies of the amino acid series PFLP or PFLF, a bispecific anti-cancer antibody that consists of the separated cancer-targeting peptide and an antigen-binding peptide that promotes T cell activity, and techniques for detecting and dealing with cancer by administering the pharmaceutical structure or the bispecific anti-cancer antibody.

Chang Gung Memorial Hospital (Taoyuan City, Taiwan)

Yu J, Yu, A, Wang S-H

6/9/2023

US11545238B2

Approaches for developing crafted polypeptides that recapitulate molecular structure functions of a fixed part of a referral protein structure, for instance, an antibody epitope or a protein binding website. The approaches consist of training a device finding out design based upon a very first set of plan records, or representations thereof, and a very first set of ratings, each plan record from the very first set of plan records being connected with each rating from the very first set of ratings.

iBio (Newark, DE, USA)

Greving MP, Taguchi AT, Hauser KE

1/3/2023

US11377485B2

Approaches for making customized Fc areas of antibodies and antibody pieces, both human and humanized, and having actually improved stability and effectiveness; antibodies consisting of Fc areas with core fucose residues eliminated, and connected to oligosaccharides making up terminal sialyl residues; antibodies consisting of uniform glycosylation of Fc areas with particular oligosaccharides; Fc areas conjugated with uniform glycoforms of monosaccharides and trisaccharides; and approaches of preparing human antibodies with customized Fc utilizing glycan engineering.

Academic Community Sinica (Taipei, Taiwan)

Wong C-H, Wu C-Y

7/5/2022

US11332540B2

A technique for dealing with a growth by administering Circ-CDH1, a circular RNA Circ-CDH1 nucleic acid particle or the protein Circ-CDH1-28 KD revealed by the circular RNA Circ-CDH1 nucleic acid particle. A monoclonal antibody anti-Circ-CDH1 is developed versus Circ-CDH1-28 KD, which can particularly find the material of a protein encoded by endogenous circular RNA Circ-CDH1, can hinder intrusion and transition of cells from growths such as glioma and breast cancer, and has broad application potential customers in scientific detection of growths and intrusion and transition treatment.

The First Affiliated Hospital, Sun Yat-sen University (Guangzhou, China)

Zhang N

5/17/2022

US11203645B2

Unique glycosynthase enzymes for glycoprotein engineering and/or uniform antibody improvement. The enzyme variations, described EndoSd-D232M and EndoSz-D234M, include the glycan conjugation and/or adjustment activity at the saved N297 glycosylation website of the Fc area of an excellent antibody.

OBI Pharma (Taipei, Taiwan)

Yu C-DT, Hsieh YH, Hsieh Y-C, Huang T-Y, Tsai Y-C, Wang N-H, Hu P-L

12/21/2021

US11192951B2

Techniques of engineering surface area charge for bispecific antibody production, consisting of offering an antibody making up a very first polypeptide making up a heavy chain variable area and a 2nd polypeptide consisting of heavy chain variable area and replacing, in a minimum of among the very first and 2nd polypeptides of the antibody, several amino acid residues of the heavy chain variable area.

Janssen Biotech (Horsham Township, PA, USA)

Nesspor T

12/7/2021

US11077144B2

A chimeric antigen receptor (CAR) in which extracellular ligand binding is a scFV stemmed from a CD19 monoclonal antibody, ideally 4G7. Polynucleotides, vectors encoding stated CAR and separated cells revealing stated CAR at their surface area, and approaches for engineering immune cells revealing 4G7-CAR at their surface area, which provides an extended ‘triggered’ state on the transduced cell.

Cellectis

Galetto R, Smith J, Scharenberg A, Schiffer-Mannioui C

8/3/2021